Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Current treatment for gastroesophageal reflux disease(GERD)confirms an unmet need in
patients, based on slow onset of action and an inability to provide 24-hour gastric acid
suppression. Clinical data on lavoltidine demonstrates a rapid onset of action, high potency,
and prolonged duration of effect after single dose. Since tolerance to the class of compounds
to which lavoltidine belongs may be dose dependent, the current study is designed to
determine if 40mg lavoltdine given for 7days develops tolerance.